Market Closed -
Nasdaq
04:00:00 2024-04-26 pm EDT
|
5-day change
|
1st Jan Change
|
2.13
USD
|
-6.17%
|
|
+11.52%
|
+136.67%
|
Fiscal Period: December |
2017
|
2018
|
2019
|
2020
|
2021
|
2022
|
---|
Capitalization
1 |
664.3
|
434.5
|
431.1
|
477.5
|
177.3
|
73.18
|
Enterprise Value (EV)
1 |
633.8
|
430.6
|
399.2
|
372.3
|
108.5
|
40.88
|
P/E ratio
|
-6.61
x
|
-7.75
x
|
-10
x
|
-6
x
|
-2.75
x
|
-2.21
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
-
|
-
|
-
|
2,652,917,178
x
|
131,246,785
x
|
54,170,110
x
|
EV / Revenue
|
-
|
-
|
-
|
2,068,339,400
x
|
80,326,725
x
|
30,256,712
x
|
EV / EBITDA
|
-6.47
x
|
-7.49
x
|
-9.92
x
|
-5.81
x
|
-1.64
x
|
-1.1
x
|
EV / FCF
|
-18
x
|
-23.8
x
|
-12.1
x
|
-13.6
x
|
-2.72
x
|
-1.54
x
|
FCF Yield
|
-5.55%
|
-4.2%
|
-8.28%
|
-7.36%
|
-36.8%
|
-65%
|
Price to Book
|
24.2
x
|
-56
x
|
14.3
x
|
5.41
x
|
6.61
x
|
-12.3
x
|
Nbr of stocks (in thousands)
|
22,845
|
23,175
|
27,816
|
39,141
|
39,142
|
38,928
|
Reference price
2 |
29.08
|
18.75
|
15.50
|
12.20
|
4.530
|
1.880
|
Announcement Date
|
4/3/18
|
4/30/19
|
4/30/20
|
4/30/21
|
4/14/22
|
4/18/23
|
Fiscal Period: December |
2017
|
2018
|
2019
|
2020
|
2021
|
2022
|
---|
Net sales
|
-
|
-
|
-
|
0.18
|
1.351
|
1.351
|
EBITDA
1 |
-97.95
|
-57.5
|
-40.23
|
-64.13
|
-66.18
|
-37.01
|
EBIT
1 |
-97.98
|
-57.54
|
-40.31
|
-64.21
|
-66.24
|
-37.24
|
Operating Margin
|
-
|
-
|
-
|
-35,672.78%
|
-4,903.03%
|
-2,756.4%
|
Earnings before Tax (EBT)
1 |
-96.39
|
-57.47
|
-40.33
|
-63.82
|
-64.64
|
-36.12
|
Net income
1 |
-91.76
|
-54.87
|
-38.08
|
-60.97
|
-64.18
|
-33.28
|
Net margin
|
-
|
-
|
-
|
-33,873.89%
|
-4,750.48%
|
-2,463.29%
|
EPS
2 |
-4.398
|
-2.421
|
-1.545
|
-2.033
|
-1.645
|
-0.8513
|
Free Cash Flow
1 |
-35.19
|
-18.1
|
-33.05
|
-27.41
|
-39.91
|
-26.58
|
FCF margin
|
-
|
-
|
-
|
-15,226.67%
|
-2,953.99%
|
-1,967.65%
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
4/3/18
|
4/30/19
|
4/30/20
|
4/30/21
|
4/14/22
|
4/18/23
|
Fiscal Period: December |
2020 Q3
|
2020 Q4
|
2021 Q1
|
2021 Q2
|
2021 Q3
|
2021 Q4
|
2022 S1
|
---|
Net sales
1 |
-
|
0.18
|
0.338
|
0.338
|
0.337
|
0.338
|
-
|
EBITDA
1 |
-15.32
|
-18.59
|
-17.4
|
-19.96
|
-18.33
|
-10.48
|
-
|
EBIT
1 |
-15.35
|
-18.62
|
-17.42
|
-19.98
|
-18.35
|
-10.49
|
-
|
Operating Margin
|
-
|
-10,341.67%
|
-5,153.85%
|
-5,910.95%
|
-5,444.81%
|
-3,104.14%
|
-
|
Earnings before Tax (EBT)
1 |
-15.18
|
-18.38
|
-17.44
|
-19.89
|
-17.56
|
-9.746
|
-
|
Net income
1 |
-14.54
|
-17.6
|
-16.99
|
-19.31
|
-18.37
|
-9.513
|
-18.49
|
Net margin
|
-
|
-9,775.56%
|
-5,026.04%
|
-5,712.43%
|
-5,451.04%
|
-2,814.5%
|
-
|
EPS
2 |
-0.4800
|
-0.5200
|
-0.4400
|
-0.4900
|
-0.4700
|
-0.2400
|
-0.4700
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
11/17/20
|
4/30/21
|
6/16/21
|
9/10/21
|
12/30/21
|
4/14/22
|
2/28/23
|
Fiscal Period: December |
2017
|
2018
|
2019
|
2020
|
2021
|
2022
|
---|
Net Debt
1 |
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
1 |
30.6
|
3.89
|
32
|
105
|
68.8
|
32.3
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
1 |
-35.2
|
-18.1
|
-33.1
|
-27.4
|
-39.9
|
-26.6
|
ROE (net income / shareholders' equity)
|
-478%
|
-616%
|
-371%
|
-104%
|
-115%
|
-310%
|
ROA (Net income/ Total Assets)
|
-257%
|
-180%
|
-97.6%
|
-49.7%
|
-41.7%
|
-36.4%
|
Assets
1 |
35.77
|
30.43
|
39.02
|
122.8
|
154
|
91.42
|
Book Value Per Share
2 |
1.200
|
-0.3300
|
1.090
|
2.260
|
0.6900
|
-0.1500
|
Cash Flow per Share
2 |
1.220
|
0.1700
|
1.290
|
2.800
|
1.070
|
0.8800
|
Capex
1 |
0.08
|
0.21
|
0
|
0.05
|
2.84
|
0.03
|
Capex / Sales
|
-
|
-
|
-
|
28.89%
|
210.51%
|
2.52%
|
Announcement Date
|
4/3/18
|
4/30/19
|
4/30/20
|
4/30/21
|
4/14/22
|
4/18/23
|
|
1st Jan change
|
Capi.
|
---|
| +136.67% | 83.1M | | -2.31% | 103B | | +0.56% | 95.28B | | +1.69% | 22.15B | | -17.37% | 21.02B | | -9.30% | 18.15B | | -41.01% | 16.74B | | -14.85% | 16.05B | | +3.21% | 13.68B | | +33.54% | 12.17B |
Bio Therapeutic Drugs
|